Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Regeneron Falls after Paring Eylea Sales Outlook

By Pharmaceutical Processing | November 4, 2014

NEW YORK (AP) — Shares of Regeneron Pharmaceuticals Inc. declined Tuesday after the company tightened its forecast for sales of Eylea, an eye drug that brings in almost all of its revenue.

Regeneron said U.S. revenue from Eylea grew 23 percent to $445 million. For the full year it now expects $1.7 billion to $1.74 billion in U.S. sales of the drug. Its previous estimate called for up to $1.8 billion in revenue.

Regeneron stock fell $23.84, or 6 percent, to $271.42 in afternoon trading.

The Tarrytown, New York, company said its total revenue from Eylea climbed 48 percent to $722 million. The drug is used to treat “wet” age-related macular degeneration and some forms of macular edema. Bayer HealthCare markets the drug in countries outside the U.S.

Regeneron said its net income totaled $79.7 million, or 70 cents per share, in the third quarter on $725.8 million in revenue. Excluding one-time charges, the company said it earned $2.52 per share.

Zacks Investment Research says analysts expected net income of $2.58 per share and revenue of $719.9 million.

Regeneron shares have increased 44 percent since the beginning of the year, while the Standard & Poor’s 500 index has increased 9 percent. The stock has increased 38 percent in the last 12 months.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE